Cel-Sci Corporation (NYSEAMERICAN:CVM) Short Interest Up 67.2% in July

Cel-Sci Corporation (NYSEAMERICAN:CVM) saw a large growth in short interest in July. As of July 31st, there was short interest totaling 1,200,354 shares, a growth of 67.2% from the July 15th total of 718,008 shares. Based on an average trading volume of 316,846 shares, the short-interest ratio is currently 3.8 days. Approximately 8.0% of the company’s stock are sold short.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in CVM. HighTower Advisors LLC acquired a new stake in shares of Cel-Sci during the 4th quarter worth about $53,000. HRT Financial LP purchased a new position in Cel-Sci in the fourth quarter valued at approximately $60,000. XTX Topco Ltd purchased a new position in Cel-Sci in the fourth quarter valued at approximately $66,000. US Bancorp DE acquired a new stake in Cel-Sci during the third quarter worth approximately $80,000. Finally, Renaissance Technologies LLC acquired a new stake in Cel-Sci during the fourth quarter worth approximately $81,000. 12.08% of the stock is owned by institutional investors and hedge funds.

Cel-Sci Trading Up 2.6%

Shares of NYSEAMERICAN:CVM opened at $1.59 on Wednesday. Cel-Sci has a 52 week low of $0.89 and a 52 week high of $13.48. The company’s 50 day moving average is $1.24 and its two-hundred day moving average is $2.61. The company has a market cap of $27.79 million, a PE ratio of -0.16 and a beta of 0.63. The company has a current ratio of 0.60, a quick ratio of 0.54 and a debt-to-equity ratio of 0.64.

Cel-Sci (NYSEAMERICAN:CVM) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.47) earnings per share (EPS) for the quarter.

About Cel-Sci

CEL-SCI Corporation is a biotechnology company focused on the development of immunotherapy products to treat cancer and infectious diseases. Founded in 1983 and headquartered in Vienna, Virginia, the company applies its proprietary LEAPS® (Ligand Epitope Antigen Presentation System) and Multikine® immunotherapy platforms to stimulate the body’s immune response against disease. CEL-SCI operates as a clinical-stage enterprise, working to translate immunological insights into therapeutic candidates.

The company’s lead product candidate, Multikine (leukineferon), is an investigational immunotherapy designed to enhance the immune system’s ability to attack head and neck cancer cells.